

Form PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER P22165
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Not Yet Assigned 10/088523	
INTERNATIONAL APPLICATION NO. PCT/JP00/06704	INTERNATIONAL FILING DATE 28 September 2000	PRIORITY DATE CLAIMED 10 October 1999	
TITLE OF INVENTION: ANTIOBESITY AGENT			
APPLICANT(S) FOR DO/EO/US: Shigeo TAKADA, Yasukazu NAGATO, Suketsune IWAGAKI, and Masahiro MURAKAMI			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.			
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input checked="" type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)) <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). "Unexecuted" <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (U.S.C. 371(c)(5)). 			
Items 11 to 16 below concern other document(s) or information included:			
<ol style="list-style-type: none"> 11. Assignee: <u>AMATO PHARMACEUTICAL PRODUCTS LTD., of Kyoto, Japan</u> 12. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> Figure of Drawing to be published: <u>Figure 1</u> 18. <input checked="" type="checkbox"/> Other items or information: Cover Letter Under 35 U.S.C. 371 and 37 C.F.R. 1.495. International Application as published (in Japanese). PCT/ISA/210 (in English and Japanese). PCT/IPEA/409 International Preliminary Examination Report. PCT/RO/101 (in Japanese). PCT/IB/308. PCT/IB/332. PCT/IB/301. PCT/IB/304. PCT/IPEA/408 (in Japanese). PCT/IB/338. PCT/IB/306. 			
<i>Claim of Priority 3/29/02</i>			

U.S. APPLICATION NO. (If known, see 37 CFR 1.492(e)) Not Yet Assigned 10/088529		INTERNATIONAL APPLICATION NO. PCT/JP00/06704	ATTORNEY'S DOCKET NUMBER P22165
19. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS	PTO USE ONLY
<p>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</p> <p>Search report has been prepared by the EPO or JPO \$ 890.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) \$ 710.00</p> <p>No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO(37 CFR 1.445(a)(2)) \$ 740.00</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00</p>			
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 0.00	
Claims	Number Filed	Number Extra	RATE
Total Claims	17	- 20 =	0 X \$18.00 \$ 0.00
Independent Claims	5	- 3 =	2 X \$84.00 \$ 168.00
Multiple dependent claim(s) (if applicable)		+ \$280.00	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =		\$1,058.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by $\frac{1}{2}$.		\$ 0.00	
SUBTOTAL =		\$1,058.00	
Processing fee of \$130.00 for furnishing the English translation later than <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$ 0.00	
Extension of Time fee in the amount of \$		\$ 0.00	
TOTAL NATIONAL FEE =		\$1,058.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$ 0.00	
TOTAL FEES ENCLOSED =		\$1,058.00	
		Amount to be refunded	\$
		Charged	\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$ 1,058.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0089</u>.</p>			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055 AT THE PRESENT ADDRESS OF:			
Bruce H. Bernstein GREENBLUM & BERNSTEIN, P.L.C. 1941 Roland Clarke Place Reston, VA 20191 (703) 716-1191			
 SIGNATURE <u>33,329</u> Bruce H. Bernstein, Reg. No. 29,027 NAME			
REGISTRATION NUMBER			



07055